Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Long-term, Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Next Previous
X
Search
Trial Profile

A Phase 3, Long-term, Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenapanor (Primary)
  • Indications Hyperphosphataemia
  • Focus Adverse reactions; Registrational
  • Sponsors Kyowa Kirin

    • Most Recent Events

    • 13 Oct 2023 According to an Ardelyx media release, data from this trial will be presented at the American Society of Nephrology (ASN) Kidney Week 2023 meeting to be held in Philadelphia, PA, November 1-5, 2023.
    • 25 Sep 2023 According to a Kyowa Kirin media release, company announced that it has received an approval for manufacturing and marketing PHOZEVEL for the improvement of hyperphosphatemia in chronic kidney disease patients on dialysis based on the results of four Phase 3 clinical trials, conducted by Kyowa Kirin in Japan, in patients with hyperphosphatemia on maintenance dialysis.
    • 31 Jul 2023 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top